Fig. 1.

Chemotherapy-resistant MPM cells display low ER stress and the adaptive UPR signalling. a qRT-PCR of 3D cells and parental cells (2D) for genes involved in the UPR (HSPA5, EIF2AK3, ATF4 and DDIT3). Data are presented as mean ± s.d. (n = 3). *P < 0.05, ***P < 0.001 and ****P < 0.0001 by unpaired two-sided t-test. b Immunoblots of 3D and parental cells for UPR-related proteins and apoptotic markers. c Viability of MPM cells after treated with cisplatin/MTA for the indicated time periods. Data are presented as mean ± s.d. (n = 3). d Immunoblots for UPR-related proteins and apoptotic markers in H28 cells that were treated as in (c). e qRT-PCR of BE454 xenograft tumours cultured ex vivo and treated with cisplatin/MTA for 72 h. Data are presented as mean ± s.d. (n = 3). ** P < 0.01 and ***P < 0.001 by unpaired two-sided t-test. (f and g) IHC for BiP (f) and Calnexin (g) in BE454 PDX tumours that were cultured and treated as in (e). Original overall magnification, ×400